A role for interleukin-33 in TH2-polarized intestinal inflammation

Mucosal Immunology

Volumn 4, Issue 5, 2011, Pages 496-502

  Seidelin, J B ^a,b   Rogler, G ^c   Nielsen, O H ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 33; INTERLEUKIN 33 ANTIBODY; ST2 ANTIBODY; UNCLASSIFIED DRUG;

ARTHRITIS; ASTHMA; CELL POLARITY; CELLULAR IMMUNITY; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; EPITHELIUM CELL; HUMAN; IMMUNE RESPONSE; INTESTINE PARASITE; MYOFIBROBLAST; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; ULCERATIVE COLITIS; UPREGULATION;

EID: 84860394671     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.22     Document Type: Review

References (81)

1. Nielsen, O. H., Seidelin, J. B., Munck, L. K. & Rogler, G. Use of biological molecules in treatment of inflammatory bowel disease. J. Intern. Med.; 269, e-pub ahead of print 17 Jan 2011.
2. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005). (Pubitemid 41587888)
3. Kobori, A. et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45, 999-1007 (2010).
4. Seidelin, J. B., Bjerrum, J. T., Coskun, M., Widjaya, B., Vainer, B. & Nielsen, O. H. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128, 80-85 (2010).
5. Baekkevold, E. S. et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79 (2003). (Pubitemid 36759592)
6. Sims, J. E. & Smith, D. E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89-102 (2010).
7. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304 (1989). (Pubitemid 20001074)
8. Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N. & Lee, R. T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007). (Pubitemid 46871338)
9. Moussion, C., Ortega, N. & Girard, J. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel'alarmin'? PLoS One 3, e3331 (2008).
10. Miller, A. M. et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346 (2008). (Pubitemid 351281600)
11. Carriere, V. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104, 282-287 (2007). (Pubitemid 46068023)
12. Prefontaine, D. et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103 (2009).
13. Wood, I. S., Wang, B. & Trayhurn, P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 384, 105-109 (2009).
14. Palmer, G. et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009).
15. Verri, W. A. Jr et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc. Natl. Acad. Sci. USA 105, 2723-2728 (2008). (Pubitemid 351520580)
16. Nile, C. J., Barksby, E., Jitprasertwong, P., Preshaw, P. M. & Taylor, J. J. Expression and regulation of interleukin-33 in human monocytes. Immunology 130, 172-180 (2010).
17. Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
18. Hsu, C. L., Neilsen, C. V. & Bryce, P. J. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One 5, e11944 (2010).
19. Prefontaine, D. et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125, 752-754 (2010).
20. Roth, G. A. et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J. Surg. Res. 163, e79-e83 (2010).
21. Marvie, P. et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J. Cell Mol. Med. 14, 1726-1739 (2010).
22. Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 107, 8017-8022 (2010).
23. Kaieda, S. et al. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J. Biol. Chem. 285, 21478-21486 (2010).
24. Matsuyama, Y. et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J. Rheumatol. 37, 18-25 (2010).
25. Chackerian, A. A., Oldham, E. R., Murphy, E. E., Schmitz, J., Pflanz, S. & Kastelein, R. A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555 (2007).
26. Greenfeder, S. A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R. A. & Ju, G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270, 13757-13765 (1995).
27. Espinassous, Q. et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J. Immunol. 183, 1446-1455 (2009).
28. Rank, M. A., Kobayashi, T., Kozaki, H., Bartemes, K. R., Squillace, D. L. & Kita, H. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009).
29. Suzukawa, M. et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181, 5981-5989 (2008).
30. Moulin, D., Donze, O., Talabot-Ayer, D., Mezin, F., Palmer, G. & Gabay, C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40, 216-225 (2007). (Pubitemid 350213434)
31. Iikura, M. et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest 87, 971-978 (2007). (Pubitemid 47429189)
32. Smithgall, M. D., Comeau, M. R., Yoon, B. R., Kaufman, D., Armitage, R. & Smith, D. E. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20, 1019-1030 (2008).
33. Bourgeois, E. et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 39, 1046-1055 (2009).
34. Pushparaj, P. N. et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. USA 106, 9773-9778 (2009).
35. Funakoshi-Tago, M. et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 20, 1679-1686 (2008).
36. Chan, W. L., Pejnovic, N., Lee, C. A. & Al-Ali, N. A. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J. Immunol. 167, 1238-1244 (2001). (Pubitemid 32703118)
37. Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852 (2007). (Pubitemid 46697925)
38. Kurowska-Stolarska, M. et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181, 4780-4790 (2008).
39. Komai-Koma, M., Xu, D., Li, Y., McKenzie, A. N., McInnes, I. B. & Liew, F. Y. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37, 2779-2786 (2007). (Pubitemid 47578297)
40. Kurowska-Stolarska, M. et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477 (2009).
41. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. & Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008). (Pubitemid 351787349)
42. Ho, L. H. et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J. Leukoc. Biol. 82, 1481-1490 (2007). (Pubitemid 350276960)
43. Allakhverdi, Z., Smith, D. E., Comeau, M. R. & Delespesse, G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179, 2051-2054 (2007).
44. Allakhverdi, Z. et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J. Allergy Clin. Immunol. 123, 472-478 (2009).
45. Ali, S., Huber, M., Kollewe, C., Bischoff, S. C., Falk, W. & Martin, M. U. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 104, 18660-18665 (2007). (Pubitemid 350210753)
46. Pecaric-Petkovic, T., Didichenko, S. A., Kaempfer, S., Spiegl, N. & Dahinden, C. A. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526-1534 (2009).
47. Schneider, E. et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J. Immunol. 183, 3591-3597 (2009).
48. Verri, W. A. Jr et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 69, 1697-1703 (2010)
49. ves-Filho, J. C. et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16, 708-712 (2010).
50. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417-426 (2002). (Pubitemid 35007355)
51. Burns, K., Martinon, F. & Tschopp, J. New insights into the mechanism of IL-1beta maturation. Curr. Opin. Immunol. 15, 26-30 (2003). (Pubitemid 35454188)
52. Martinon, F. & Tschopp, J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14, 10-22 (2007). (Pubitemid 44911890)
53. Ohno, T. et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183, 7890-7897 (2009).
54. Cayrol, C. & Girard, J. P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106, 9021-9026 (2009).
55. Luthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009).
56. Suzukawa, M. et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab. Invest. 88, 1245-1253 (2008).
57. Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J. & Kuchler, A. M. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol. 30, 227-233 (2009).
58. Golstein, P. & Kroemer, G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32, 37-43 (2007). (Pubitemid 46043552)
59. Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231-241 (2008). (Pubitemid 351301823)
60. Raucci, A., Palumbo, R. & Bianchi, M. E. HMGB1: a signal of necrosis. Autoimmunity 40, 285-289 (2007). (Pubitemid 46845522)
61. Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002). (Pubitemid 34773774)
62. Kazama, H., Ricci, J. E., Herndon, J. M., Hoppe, G., Green, D. R. & Ferguson, T. A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32 (2008). (Pubitemid 351952462)
63. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
64. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009).
65. Maizels, R. M., Pearce, E. J., Artis, D., Yazdanbakhsh, M. & Wynn, T. A. Regulation of pathogenesis and immunity in helminth infections. J. Exp. Med. 206, 2059-2066 (2009).
66. Niessner, M. & Volk, B. A. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol. 101, 428-435 (1995).
67. Kuchler, A. M. et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173, 1229-1242 (2008).
68. Beltran, C. J. et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1097-1107 (2010).
69. Sponheim, J. et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804-2815 (2010).
70. Xu, D. et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105, 10913-10918 (2008).
71. Hudson, C. A., Christophi, G. P., Gruber, R. C., Wilmore, J. R., Lawrence, D. A. & Massa, P. T. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84, 631-643 (2008).
72. Humphreys, N. E., Xu, D., Hepworth, M. R., Liew, F. Y. & Grencis, R. K. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180, 2443-2449 (2008).
73. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107, 18581-18586 (2010).
74. Liu, X., Li, M., Wu, Y., Zhou, Y., Zeng, L. & Huang, T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386, 181-185 (2009).
75. Kearley, J., Buckland, K. F., Mathie, S. A. & Lloyd, C. M. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 179, 772-781 (2009).
76. Targan, S. R. & Karp, L. C. Defects in mucosal immunity leading to ulcerative colitis. Immunol. Rev. 206, 296-305 (2005). (Pubitemid 41105177)
77. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003). (Pubitemid 37328672)
78. Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550-564 (2005). (Pubitemid 41096643)
79. Fuss, I. J. et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996). (Pubitemid 126449643)
80. Coskun, M., Olsen, J., Seidelin, J. B. & Nielsen, O. H. The involvement of MAP kinases in inflammatory bowel disease. Clin. Chim. Acta. 412, 513-520 (2011).
81. Andresen, L., Jorgensen, V. L., Perner, A., Hansen, A., Eugen-Olsen, J. & Rask-Madsen, J. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54, 503-509 (2005). (Pubitemid 40395502)